Skip to main navigationSkip to main content
The University of Southampton
Southampton Clinical Trials Unit

REMoDL-B Trial


REMoDL-B: A Randomised Evaluation of Molecular guided therapy for Diffuse Large B-cell Lymphoma with Bortezomib 


REMoDL-B is a multi-centre, open label randomised trial comparing the standard care treatment of R-CHOP with R-CHOP plus bortezomib (RB-CHOP). All patients will receive one cycle of R-CHOP. They will then be randomised to receive either R-CHOP or RB-CHOP on the basis of the molecular profile of their lymphoma and the IPI score. 


Primary Objectives:

  • To demonstrate superior clinical efficacy, as measured by Progression-free survival (PFS), of bortezomib in combination with rituximab and CHOP (RB-CHOP) versus  R-CHOP alone for the treatment of previously untreated patients with DLBCL.
  • To assess whether the molecular phenotype, either activated B-cell (ABC) like or germinal centre B-cell (GCB) like, of DLBCL determines the benefit from the addition of bortezomib.

Secondary Objectives:

  • To compare overall survival (OS) between both treatment and molecular groups
  • To compare event free survival (EFS) between both treatment and molecular groups
  • To compare disease free survival (DFS) between both treatment and molecular groups
  • To compare time to progression (TTP) between both treatment and molecular groups
  • To compare response duration (RD) between both treatment and molecular groups
  • To compare overall response rate (ORR) and complete response rate (CR) between both treatment groups
  • To assess differences in toxicity between assigned treatments
  • To assess quality of life and chemotherapy induced peripheral neuropathy reported by patients across the two different induction treatments
  • To demonstrate that accurate molecular profiling may be conducted in real-time and relate this to immunohistochemical algorithms.
  • To perform exploratory analysis comparing aberrations in the NF-кB pathway to clinical outcomes by treatment groups

Trial Design

Stratified open-label multicentre randomised Phase III. A novel adaptive trial design will be employed with 2 interim analysis to explore safety and efficacy in the GCB arm patients treated with RB- CHOP. Modified to randomised Phase II in ABC patients only if GCB arm closed.

Trial Status

Closed to reruitment - Currently in follow-up


1132 patients with Diffuse Large B Cell Lymphoma from >50 sites throughout the UK and Switzerland. 

Trial Team:

Senior Trial Manager:

Josh Caddy (023 8120 5537)

Trial Manager:

Marina Lee  (023 8120 5539)

Clinical Data Coordinator:

Zoë Konn (023 8120 5677)

Contact information


Fax: 0844 7740 621

SAE Reporting: 


We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.